Facts & Figures
Science for a better life - Medical Progress for the Benefit of the Patient
Facts and Figures at a glance
| Research expenses 2007 | 1,700 € million |
| Proportion of total Bayer group research expenses 2007 | 65.9% |
| Employees in Research & Development | 6,620 (as of Dec. 31, 2007) |
| Main research locations | Berlin and Wuppertal, Germany and Berkeley, USA |
| Research focus |
|
Research activities 2007
In 2007 we invested 1,700 million (2006: 1,426 million) in r&d in the Pharmaceuticals and Consumer Health segments to lay the foundations for the introduction of further innovative products in the subgroup’s expanding markets. This represented 65.9 percent of the Bayer Group’s entire r&d expenditures and was equivalent to 11.5 percent of sales. In connection with the integration of Schering AG, Berlin, Germany, we have carried out a strategic realignment and reorganized our global pharmaceutical research and development to adjust to the new situation. In drug discovery we now focus on four growth areas: oncology, cardiology, women’s healthcare and diagnostic imaging.
Research locations
The Berlin and Wuppertal locations have signifi cant capabilities and activities in the identifi cation of molecular targets and the development and optimization of lead substances, as well as in drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.
Berkeley is an important global research and development center for protein-based active ingredients and is home to the biotechnological production facility for Kogenate®. Bayer HealthCare’s u.s. research sites in West Haven, Connecticut, and Richmond, California, have been or will be closed.
